For what it is worthThe stock market is a discounting mechanism, that is how it works. The market anticipates future events for a company and then applies a discount to arrive at a reasonable value for a company today and then adjusts the value of that company as events unfold.So if we were to apply one posters reasoning for MedX you would not own any shares in the market and bury your life savings in the backyard. The reality is telemedicine shares are trading at 25 x their enterprise value today. The telemedicine space is the hottest space in the market currently, there will be big winners like Teledoc, Apple and Google and a number of midraange players for quite so time to come. I believe their will be additional specialty telemedicine companies that willdominate a niche and then get aquired.Look at the recent trading on ADK https://stockhouse.com/companies/quote?symbol=v.adk
Specialty company AI/telemedicine, they land a pilot with a national chain and they are off to the 25X enterprise valuation territory.
MDX has proved the concept of teledermatologyin Norway. Read the independent report here;
https://www.sciencedirect.com/science/article/pii/S1551741116305812
So MedX had to stop and build a complete end to end solution to be a scalable company. It has now completed that and has opened up globally. MedX announced Brazil and gave guidance that we will see revenue from Brazil in Q3-Q4 but shareholders do not believe this to be true. Time will tell. I believe MedX like ADK needs to land a North American trial with a major brand and then perhaps MDX will garner the attention it deserves.
In a recent presentation MedX declared it was a leader in teledermatology. They provided a number of points that expressed what it takes to declare yourself as a leader in teledermatology.
I have listed them below;
Leaders in Teledermatology must have;
•An image capture system that provides the highest definition images, no images or patient information can be stored on the image capture device or corresponding computer
•A Patient Management System that captures the patient’s history, complete medical information, the location of the suspicious mole/lesion/rash
•A navigator system that can complete the patients “circle of care” ensuring patient receives same follow-up care as an in-clinic assessment
•A fully secure telemedicine platform that provides patients with complete privacy protection, independently threat tested and fully compliant with national privacy standards (HIPAA, GDPR)
• Images cannot leave the country of origin
•The capability to store the patient’s images/personal information securely for minimum of 10 years.
•The capability to rescan the patient’s condition at any time and compare the images to earlier images
•Regulatory Authority compliant (FDA, CE, Health Canada, ARGT)
So if posters want to find another company in the teledermatology space that has these attributes please post them as it would be helpful for comparative purposes. For posters who think management has squandered their money and not built anything that is saleable I would challenge that notion. Posters who think this is a pump and dump well that is just silly.
Perhaps what has really happened to MedX is the management team actually worked deeply with their Medical Advisory Board to understand what the market really needs to make teledermatology a success and are now they have finally launched that offering globally.
The signs are all there so I would suggest ignore the noise and pay attention to the signal. Have a great Thanksgiving. Stay safe